Soligenix, Inc. (NASDAQ:SNGX) Director Mark E. Pearson acquired 170,000 shares of the firm’s stock in a transaction on Wednesday, October 17th. The shares were bought at an average cost of $1.16 per share, for a total transaction of $197,200.00. Following the completion of the acquisition, the director now directly owns 2,500,000 shares of the company’s stock, valued at approximately $2,900,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Shares of SNGX traded down $0.05 on Wednesday, hitting $1.08. The company’s stock had a trading volume of 440,400 shares, compared to its average volume of 190,636. Soligenix, Inc. has a fifty-two week low of $0.91 and a fifty-two week high of $3.70.

Soligenix (NASDAQ:SNGX) last announced its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.06). The business had revenue of $1.70 million during the quarter, compared to analyst estimates of $1.20 million. Soligenix had a negative return on equity of 176.04% and a negative net margin of 120.14%. On average, sell-side analysts expect that Soligenix, Inc. will post -0.68 EPS for the current fiscal year.

Separately, Maxim Group reaffirmed a “buy” rating and set a $4.00 price objective on shares of Soligenix in a report on Thursday, September 13th.

Soligenix Company Profile

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer.

Featured Article: Asset Allocation, Balancing Your Investments

Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with's FREE daily email newsletter.